2
|
Zhong Y, Zhang BW, Li JT, Zeng X, Pei JX, Zhang YM, Yang YX, Li FL, Deng Y, Zhao Q. Ethanol extract of Herpetospermum caudigerum Wall ameliorates psoriasis-like skin inflammation and promotes degradation of keratinocyte-derived ICAM-1 and CXCL9. JOURNAL OF INTEGRATIVE MEDICINE 2023; 21:584-592. [PMID: 37989697 DOI: 10.1016/j.joim.2023.11.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2023] [Accepted: 10/25/2023] [Indexed: 11/23/2023]
Abstract
OBJECTIVE To explore whether the ethanol extract of Herpetospermum caudigerum Wall (EHC), a Xizang medicinal plant traditionally used for treating liver diseases, can improve imiquimod-induced psoriasis-like skin inflammation. METHODS Immunohistochemistry and immunofluorescence staining were used to determine the effects of topical EHC use in vivo on the skin pathology of imiquimod-induced psoriasis in mice. The protein levels of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and interleukin-17A (IL-17A) in mouse skin samples were examined using immunohistochemical staining. In vitro, IFN-γ-induced HaCaT cells with or without EHC treatment were used to evaluate the expression of keratinocyte-derived intercellular cell adhesion molecule-1 (ICAM-1) and chemokine CXC ligand 9 (CXCL9) using Western blotting and reverse transcription-quantitative polymerase chain reaction. The protein synthesis inhibitor cycloheximide and proteasome inhibitor MG132 were utilized to validate the EHC-mediated mechanism underlying degradation of ICAM-1 and CXCL9. RESULTS EHC improved inflammation in the imiquimod-induced psoriasis mouse model and reduced the levels of IFN-γ, TNF-α, and IL-17A in psoriatic lesions. Treatment with EHC also suppressed ICAM-1 and CXCL9 in epidermal keratinocytes. Further mechanistic studies revealed that EHC suppressed keratinocyte-derived ICAM-1 and CXCL9 by promoting ubiquitin-proteasome-mediated protein degradation rather than transcriptional repression. Seven primary compounds including ehletianol C, dehydrodiconiferyl alcohol, herpetrione, herpetin, herpetotriol, herpetetrone and herpetetrol were identified from the EHC using ultra-performance liquid chromatography-quadrupole-time of flight-mass spectrometry. CONCLUSION Topical application of EHC ameliorates psoriasis-like skin symptoms and improves the inflammation at the lesion sites. Please cite this article as: Zhong Y, Zhang BW, Li JT, Zeng X, Pei JX, Zhang YM, Yang YX, Li FL, Deng Y, Zhao Q. Ethanol extract of Herpetospermum caudigerum Wall ameliorates psoriasis-like skin inflammation and promotes degradation of keratinocyte-derived ICAM-1 and CXCL9. J Integr Med. 2023; 21(6): 584-592.
Collapse
Affiliation(s)
- Ya Zhong
- Engineering Research Center of Sichuan-Xizang Traditional Medicinal Plant, Chengdu University, Chengdu 610106, Sichuan Province, China; Institute of Cancer Biology and Drug Discovery, Chengdu University, Chengdu 610106, Sichuan Province, China; School of Food and Biological Engineering, Chengdu University, Chengdu 610106, Sichuan Province, China
| | - Bo-Wen Zhang
- Engineering Research Center of Sichuan-Xizang Traditional Medicinal Plant, Chengdu University, Chengdu 610106, Sichuan Province, China; Institute of Cancer Biology and Drug Discovery, Chengdu University, Chengdu 610106, Sichuan Province, China; School of Food and Biological Engineering, Chengdu University, Chengdu 610106, Sichuan Province, China
| | - Jin-Tao Li
- Engineering Research Center of Sichuan-Xizang Traditional Medicinal Plant, Chengdu University, Chengdu 610106, Sichuan Province, China; Institute of Cancer Biology and Drug Discovery, Chengdu University, Chengdu 610106, Sichuan Province, China; School of Pharmacy, Chengdu University, Chengdu 610106, Sichuan Province, China
| | - Xin Zeng
- Engineering Research Center of Sichuan-Xizang Traditional Medicinal Plant, Chengdu University, Chengdu 610106, Sichuan Province, China; Institute of Cancer Biology and Drug Discovery, Chengdu University, Chengdu 610106, Sichuan Province, China; School of Pharmacy, Chengdu University, Chengdu 610106, Sichuan Province, China
| | - Jun-Xia Pei
- Engineering Research Center of Sichuan-Xizang Traditional Medicinal Plant, Chengdu University, Chengdu 610106, Sichuan Province, China; Institute of Cancer Biology and Drug Discovery, Chengdu University, Chengdu 610106, Sichuan Province, China; School of Food and Biological Engineering, Chengdu University, Chengdu 610106, Sichuan Province, China
| | - Ya-Mei Zhang
- Key Laboratory of Clinical Genetics, Affiliated Hospital of Chengdu University, Chengdu 610106, Sichuan Province, China
| | - Yi-Xi Yang
- Engineering Research Center of Sichuan-Xizang Traditional Medicinal Plant, Chengdu University, Chengdu 610106, Sichuan Province, China; Institute of Cancer Biology and Drug Discovery, Chengdu University, Chengdu 610106, Sichuan Province, China; School of Food and Biological Engineering, Chengdu University, Chengdu 610106, Sichuan Province, China
| | - Fu-Lun Li
- Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
| | - Yu Deng
- Engineering Research Center of Sichuan-Xizang Traditional Medicinal Plant, Chengdu University, Chengdu 610106, Sichuan Province, China; Institute of Cancer Biology and Drug Discovery, Chengdu University, Chengdu 610106, Sichuan Province, China; School of Basic Medical Sciences, Chengdu University, Chengdu 610106, Sichuan Province, China.
| | - Qi Zhao
- Engineering Research Center of Sichuan-Xizang Traditional Medicinal Plant, Chengdu University, Chengdu 610106, Sichuan Province, China; Institute of Cancer Biology and Drug Discovery, Chengdu University, Chengdu 610106, Sichuan Province, China; School of Food and Biological Engineering, Chengdu University, Chengdu 610106, Sichuan Province, China.
| |
Collapse
|
12
|
Li J, Jing J, Bai Y, Li Z, Xing R, Tan B, Ma X, Qiu WW, Du C, Du B, Yang F, Tang J, Siwko S, Liu M, Chen H, Luo J. SH479, a Betulinic Acid Derivative, Ameliorates Experimental Autoimmune Encephalomyelitis by Regulating the T Helper 17/Regulatory T Cell Balance. Mol Pharmacol 2017; 91:464-474. [PMID: 28213589 DOI: 10.1124/mol.116.107136] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Accepted: 02/15/2017] [Indexed: 12/19/2022] Open
Abstract
CD4+ T helper cells, especially T helper 17 (TH17) cells, combined with immune regulatory network dysfunction, play key roles in autoimmune diseases including multiple sclerosis (MS). Betulinic acid (BA), a natural pentacyclic triterpenoid, has been reported to be involved in anti-inflammation, in particular having an inhibitory effect on proinflammatory cytokine interleukin 17 (IL-17) and interferon-γ (IFN-γ) production. In this study, we screened BA derivatives and found a BA derivative, SH479, that had a greater inhibitory effect on TH17 differentiation. Our further analysis showed that SH479 had a greater inhibitory effect on TH17 and TH1, and a more stimulatory effect on regulatory T (Treg) cells. To evaluate the effects of SH479 on autoimmune diseases in vivo, we employed the extensively used MS mouse model experimental autoimmune encephalomyelitis (EAE). Our results showed that SH479 ameliorated clinical and histologic signs of EAE in both prevention and therapeutic protocols by regulating the TH17/Treg balance. SH479 dose-dependently reduced splenic lymphocyte proinflammatory factors and increased anti-inflammatory factors. Moreover, SH479 specifically inhibited splenic lymphocyte viability from EAE mice but not normal splenic lymphocyte viability. At the molecular level, SH479 inhibited TH17 differentiation by regulating signal transducer and activator of transcription-3 (STAT3) phosphorylation, DNA binding activity, and recruitment to the Il-17a promoter in CD4+ T cells. Furthermore, SH479 promoted the STAT5 signaling pathway and inhibited the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. Together, our data demonstrated that SH479 ameliorated EAE by regulating the TH17/Treg balance through inhibiting the STAT3 and NF-κB pathways while activating the STAT5 pathway, suggesting that SH479 is a potential novel drug candidate for autoimmune diseases including MS.
Collapse
Affiliation(s)
- Jing Li
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Ji Jing
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Yang Bai
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Zhen Li
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Roumei Xing
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Binhe Tan
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Xueyun Ma
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Wen-Wei Qiu
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Changsheng Du
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Bing Du
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Fan Yang
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Jie Tang
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Stefan Siwko
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Mingyao Liu
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Huaqing Chen
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| | - Jian Luo
- Shanghai Fengxian District Central Hospital, Shanghai, People's Republic of China (J.Li); Shanghai Fengxian District Central Hospital and East China Normal University Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (J.J., Y.B., Z.L., R.X., B.T., X.M., B.D., M.L., H.C., J.Luo); Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China (W.-W.Q., F.Y., J.T.); Laboratory of Receptor-Based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China (C.D.); Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas (S.S., M.L.)
| |
Collapse
|